Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.39 |
| ▸ | PRKCG | P05129 | 3/20 | 0.39 |
| ▸ | PRKCB | P05771 | 3/20 | 0.39 |
| ▸ | PRKCA | P17252 | 3/20 | 0.39 |
| ▸ | PRKCH | P24723 | 3/20 | 0.39 |
| ▸ | PRKCI | P41743 | 3/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | PRKACG | P22612 | 2/20 | 0.39 |
| ▸ | PRKACB | P22694 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909501 | 0.89 | CHRM1 (0.49) | CNR1PRKCEPRKCDPRKD1PRKD3 | |
| SCHEMBL2908979 | 0.85 | CNR1 (0.38) | CNR1PRKCEPRKCDPRKD1PRKD3 | |
| SCHEMBL7429827 | 0.82 | PRKD3 (0.60) | CNR1PRKCEPRKCDPRKD1PRKD3 | |
| SCHEMBL2909739 | 0.82 | ROCK2 (0.47) | CNR1PRKCEPRKCDPRKD1SMN1; SMN2 | |
| SCHEMBL2910377 | 0.78 | ROCK2 (0.49) | CNR1PRKCEPRKCDPRKD1SMN1; SMN2 | |
| SCHEMBL23795306 | 0.78 | CNR1 (0.44) | CNR1ALOX15ROCK2ROCK1 | |
| SCHEMBL30439348 | 0.78 | CNR1 (0.44) | CNR1ALOX15ROCK2ROCK1 | |
| SCHEMBL24177978 | 0.78 | CNR1 (0.44) | CNR1ALOX15ROCK2ROCK1 | |
| SCHEMBL13513879 | 0.77 | PRKCD (0.65) | PRKCEPRKCDPRKD1PRKD3PRKCG | |
| SCHEMBL7327006 | 0.76 | ROCK2 (0.39) | CNR1PRKCEPRKCDPRKD1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-0956865-B2 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| EP-0956865-B1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI PHARMA CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6906061-B2 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2005-06-14 | — | — | US | disclosed |
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004062666-A2 | USE OF RHO-KINASE INHIBITORRS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | UNIVERSITY COLLEGE LONDON (GB) | 2004-07-29 | — | — | WO | disclosed |
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | UEHATA MASAYOSHI (JP) | 2003-07-17 | — | — | US | disclosed |
| US-6451825-B1 | FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5747507-A | MYOCARDIAL DISEASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0654266-A1 | CARDIAC PROTECTIVE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0187371-B1 | SUBSTITUTED ISOQUINOLINESULFONYL COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-06-19 | — | — | EP | disclosed |
| US-4678783-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVES, ARTERIOSCLEROSIS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0187371-A2 | Substituted isoquinolinesulfonyl compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | CNR1 1669/4885PRKCE 257/4885PRKCD 486/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | CNR1 4621/4885PRKCE 170/4885PRKCD 375/4885 |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | CNR1 1669/4885PRKCE 257/4885PRKCD 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.